Do-Not-Call Improvement Act of 2007

The Do-Not-Call Improvement Act of 2007 is a federal law that amends the Telemarketing Sales Rule (TSR) and strengthens the protections for consumers against unwanted telemarketing calls.

The key features of the Act are:

·National Do-Not-Call Registry: The Act establishes a national Do-Not-Call Registry, which is maintained by the Federal Trade Commission (FTC). Consumers can add their phone numbers to the registry to stop telemarketers from calling them.

·Telemarketing Rules: The Act strengthens the rules that telemarketers must follow when calling consumers. For example, telemarketers are required to provide their name and phone number, the name of the person or company on whose behalf they are calling, and a description of the goods or services they are selling.

·Abandoned Calls: The Act prohibits telemarketers from making "abandoned calls" (i.e., calls that are not answered or are answered by a machine). Telemarketers must ensure that at least 97% of their calls are answered by a live person.

·Caller ID: The Act requires telemarketers to transmit accurate caller ID information.

5. Enforcement: The Act gives the FTC and state attorneys general the authority to enforce the Do-Not-Call Registry and the telemarketing rules. Violators can face fines and other penalties. As it relates to employee benefits, the Act may impact telemarketing efforts by companies that provide insurance or other benefits-related products or services. Companies must comply with the rules and regulations outlined in the Act when conducting telemarketing campaigns, and may need to ensure that their tele-marketing activities do not violate the rights of consumers or employees.

Next Up

Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.
Most U.S. employers now offer paid maternity leave beyond the legal minimum, but coverage varies widely once you look past the basics. According to Mployer Insights' 2026 analysis of more than 50,000 employer benefit plans, 68% of employers provide paid maternity leave on top of short-term disability, typically adding 8 extra weeks, and half now cover 100% of salary during the disability period. Support drops off from there: only 41% of employers offer paid bonding leave for non-birth parents, and advanced family-building benefits remain even less common, with just 28% covering IVF and 11% offering adoption financial assistance. The data suggests that while baseline maternity leave has become standard, more comprehensive family-building support is still the exception rather than the norm.